Core Insights - Cencora reported quarterly earnings of $3.84 per share, exceeding the Zacks Consensus Estimate of $3.79 per share, and showing an increase from $3.34 per share a year ago, resulting in an earnings surprise of +1.32% [1] - The company achieved revenues of $83.73 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.69% and reflecting a year-over-year increase from $79.05 billion [2] - Cencora's stock has increased by approximately 53.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 15.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $4.05, with projected revenues of $87.22 billion, and for the current fiscal year, the EPS estimate is $17.37 on revenues of $342.35 billion [7] - The estimate revisions trend for Cencora was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical Services industry, to which Cencora belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting that the industry's outlook may impact stock performance [8] - Another company in the same industry, Ardent Health, is expected to report quarterly earnings of $0.42 per share, reflecting a year-over-year change of +121.1%, with revenues anticipated to be $1.55 billion, up 7.1% from the previous year [9][10]

Financial Performance - Fiscal Year 2025 - Cencora's revenue increased by 93% year-over-year to $3213 billion[22] - Adjusted diluted earnings per share grew by 163% year-over-year to $1600[21] - Adjusted operating income increased by 158% year-over-year[20] - U S Healthcare Solutions segment operating income increased by 218% year-over-year[20] - International Healthcare Solutions segment operating income declined by 91% year-over-year[20] Q4 Fiscal Year 2025 Performance - Revenue grew by 59% year-over-year[12] - Consolidated adjusted operating income increased by 202% year-over-year[12] - U S Healthcare Solutions segment operating income increased by 251% year-over-year[12] - International Healthcare Solutions segment operating income declined by 20% year-over-year[12] Fiscal Year 2026 Guidance - Revenue is projected to grow by 5% to 7%[25] - Adjusted operating income is expected to grow by 8% to 10%[10] - Adjusted diluted earnings per share are projected to be between $1745 and $1775[25]

Core Insights - Cencora plans to invest over $1 billion through 2030 to expand its U.S. distribution network, forecasting adjusted profit for next year above Wall Street expectations [1][3] Investment Plans - The company will build a second national distribution center in Harrison, Ohio, and expand sites in California and Alabama [1][2] - The Ohio hub will be 530,000 square feet and is expected to be operational by spring 2027, featuring advanced automation [2] - A new 430,000-square-foot distribution center in Fontana, California, will nearly double the size of the current site and is targeted to open by fall 2026 [3] Financial Performance - Cencora expects adjusted profit per share for 2026 to be between $17.45 and $17.75, slightly above analysts' expectations of $17.5 [3] - The company's U.S. Healthcare Solutions unit reported a 5.7% increase in sales to $75.79 billion for the quarter ended September 30, driven by strong prescription volumes of GLP-1 class drugs and specialty medicines [4] - Cencora reported fourth-quarter profit of $3.84 per share, exceeding analysts' estimates of $3.79 per share, with total sales of $83.73 billion, above the expected $83.46 billion [5]

Group 1 - The company will open two new distribution centers to meet the increasing demand for GLP-1s and other refrigerated medications [1] - A third distribution center will be expanded to further accommodate the surge in demand [1]

Financial Performance - Fourth quarter revenue was $83.7 billion, a 5.9% year-over-year increase, while fiscal year 2025 revenue reached $321.3 billion, up 9.3% year-over-year[1] - Fourth quarter GAAP diluted EPS was $(1.75), a decrease from $0.02 in the prior year, while adjusted diluted EPS increased 15.0% to $3.84[1][4] - Gross profit for the fourth quarter was $3.0 billion, an 18.5% increase year-over-year, with gross profit margin rising to 3.53%[4] - Fiscal year 2025 adjusted diluted EPS was $16.00, a 16.3% increase from the previous year[13] - Total revenue for Fiscal Year 2025 was $321.3 billion, representing a 9.3% increase from $293.96 billion in Fiscal Year 2024[32] - Gross profit for Fiscal Year 2025 was $11.48 billion, a 15.8% increase from $9.91 billion in Fiscal Year 2024[32] - Operating income for Fiscal Year 2025 was $2.63 billion, reflecting a 20.8% increase from $2.18 billion in Fiscal Year 2024[32] - Net income attributable to Cencora, Inc. for Fiscal Year 2025 was $1.55 billion, a 3.0% increase from $1.51 billion in Fiscal Year 2024[32] - Basic earnings per share for Fiscal Year 2025 increased to $8.02 from $7.60 in Fiscal Year 2024, representing a 5.5% growth[32] - Adjusted non-GAAP earnings per share for the fiscal year ended September 30, 2025, was $16.00, up from the previous year[43] - Cencora, Inc. reported total revenue of $321.33 billion for the fiscal year ended September 30, 2025, representing a 9.3% increase from $293.96 billion in 2024[52] - Operating income for Cencora, Inc. increased by 20.8% to $2.63 billion in 2025, compared to $2.18 billion in 2024[52] - U.S. Healthcare Solutions revenue grew by 9.7% to $290.98 billion in 2025, while International Healthcare Solutions revenue increased by 6.1% to $30.37 billion[52] Expenses and Impairments - Operating expenses in the fourth quarter were $2.9 billion, a 24.1% increase year-over-year, primarily due to a $723.9 million goodwill impairment charge[4] - The company reported a $723.9 million impairment of assets, including goodwill, impacting overall profitability[37] - The company incurred a $113.5 million impairment of an equity investment and a $35.5 million loss on the divestiture of non-core businesses during the fiscal year[34] - The company reported net cash used in investing activities of $4,977.3 million in 2025, significantly higher than $618.1 million in 2024, indicating increased investment activity[57] Guidance and Future Projections - The company raised its long-term guidance expectations, reflecting confidence in its growth strategy and market position[2] - Fiscal Year 2026 revenue guidance is projected to grow by 5% to 7%, with actual revenue for Fiscal 2025 at $321.3 billion[18] - Adjusted operating income for Fiscal Year 2026 is expected to increase by 8% to 10%, compared to $4.2 billion in Fiscal 2025[18] - Adjusted diluted earnings per share for Fiscal Year 2026 is forecasted to be between $17.45 and $17.75, up from $16.00 in Fiscal 2025[18] - The U.S. Healthcare Solutions Segment is anticipated to grow by 5% to 7%, with actual revenue of $285.0 billion in Fiscal 2025[18] - The International Healthcare Solutions Segment is expected to grow by 6% to 8%, with actual revenue of $28.3 billion in Fiscal 2025[18] Investments and Capital Expenditures - The company announced a $1 billion investment plan through 2030 to enhance its U.S. distribution network and increase capacity[14] - The company reported capital expenditures of $668.0 million for the fiscal year 2025, compared to $487.2 million in 2024, reflecting a 37.1% increase[57] Shareholder Returns - The quarterly dividend was increased by 9% to $0.60 per share, payable on December 1, 2025[15] Cash Flow and Debt - Net cash provided by operating activities increased to $3,875.1 million in 2025 from $3,484.7 million in 2024, reflecting a rise of 11.2%[57] - The company experienced a net debt borrowing of $3,195.7 million in 2025, contrasting with a repayment of $385.5 million in 2024[57] - Cash, cash equivalents, and restricted cash at the end of fiscal year 2025 totaled $4,394.5 million, up from $3,297.9 million in 2024, marking an increase of 33.4%[57] - Adjusted free cash flow for the fiscal year 2025 was $2,970.8 million, calculated as net cash provided by operating activities minus capital expenditures[62] Segment Performance - U.S. Healthcare Solutions revenue was $75.8 billion in the fourth quarter, a 5.7% increase, while International Healthcare Solutions revenue was $7.9 billion, up 7.6%[8][10] - Operating income for U.S. Healthcare Solutions segment increased by 21.8% to $3.57 billion in 2025[52]

Core Insights - Cencora, Inc. reported a revenue increase of 5.9% to $83.7 billion for the fourth quarter of fiscal year 2025, ending September 30, 2025 [1] - For the entire fiscal year 2025, revenue rose by 9.3% to $321.3 billion [1] - The diluted earnings per share (EPS) for the September quarter of fiscal 2025 was $(1.75), a decline from $0.02 in the same quarter of the previous year [1]

Core Insights - BD (Becton, Dickinson and Company) has received FDA 510(k) clearance and CE marking for its Enteric Bacterial Panel (EBP) and Enteric Bacterial Panel plus (EBP plus) for the BD COR™ System, enhancing diagnostic capabilities for gastrointestinal infections [1][2]. Group 1: Product Features and Benefits - The EBP and EBP plus utilize advanced Polymerase Chain Reaction (PCR) technology to test a wide range of gastrointestinal bacterial pathogens from a single stool swab, streamlining workflows for clinicians [1][2]. - The EBP plus is the only high-throughput, bacterial-only molecular panel that detects Enterotoxigenic Escherichia coli (ETEC) and associated toxins, improving patient management and reducing unnecessary antibiotic use [3]. - The BD COR™ System can automate nearly 1,650 tests and deliver up to 1,000 sample results in 24 hours, maximizing efficiency with minimal manual interaction [4]. Group 2: Market Context and Impact - Gastrointestinal infections lead to over 1.7 million deaths globally each year, with significant healthcare burdens in the U.S., including 179 million outpatient visits and 500,000 hospitalizations annually due to diarrhea [1]. - The introduction of these panels addresses the urgent need for rapid and accurate diagnostics, which is critical for improving patient outcomes and supporting antimicrobial stewardship [1][2]. Group 3: Company Overview - BD is one of the largest global medical technology companies, focused on advancing health through innovative technology and solutions that enhance clinical therapy and healthcare delivery [7][8]. - The company has a strong commitment to improving the safety and efficiency of healthcare processes, with a presence in virtually every country and partnerships aimed at addressing global health challenges [8].

Core Insights - Cencora (COR) is expected to report quarterly earnings of $3.79 per share, reflecting a year-over-year increase of 13.5% [1] - Projected revenues for the quarter are anticipated to be $83.16 billion, which represents a 5.2% increase from the previous year [1] - The consensus EPS estimate has been adjusted upward by 0.3% over the past 30 days, indicating a reassessment by analysts [1] Revenue Projections - Analysts project 'Revenue- Total International Healthcare Solutions' to reach $8.00 billion, indicating an 8.3% increase from the prior-year quarter [4] - The consensus for 'Revenue- Total U.S. Healthcare Solutions' is $75.11 billion, reflecting a year-over-year change of 4.8% [4] - 'Revenue- International Healthcare Solutions- Alliance Healthcare' is expected to be $6.47 billion, showing an 8.9% year-over-year increase [5] - 'Revenue- U.S. Healthcare Solutions- Animal Health' is estimated at $1.36 billion, suggesting a decline of 3.1% year over year [5] - The estimate for 'Revenue- U.S. Healthcare Solutions- Human Health' stands at $73.80 billion, indicating a 5% increase from the previous year [5] - 'Revenue- International Healthcare Solutions- Other Healthcare Solutions' is forecasted to reach $1.61 billion, reflecting an 11.7% increase [6] Operating Income Estimates - 'Operating income- Non-GAAP- International Healthcare Solutions' is projected to be $170.29 million, compared to $153.67 million from the previous year [6] - 'Operating income- Non-GAAP- U.S. Healthcare Solutions' is expected to arrive at $840.57 million, up from $697.38 million year-over-year [7] Stock Performance - Cencora shares have increased by 10.6% over the past month, outperforming the Zacks S&P 500 composite, which rose by 2.1% [7] - Cencora holds a Zacks Rank 3 (Hold), indicating it is expected to closely follow overall market performance in the near term [7]

Core Insights - Cencora, Inc. is a leading global healthcare solutions provider with a market cap of $63.8 billion, focusing on sourcing and distributing pharmaceutical and healthcare products while offering logistics, data analytics, and commercialization services [1] Financial Performance - Cencora is expected to announce its fiscal Q4 2025 results on November 5, with analysts forecasting an adjusted EPS of $3.79, representing a 13.5% increase from $3.34 in the same quarter last year [2] - For fiscal 2025, the projected adjusted EPS is $15.93, reflecting a 15.8% increase from $13.76 in fiscal 2024 [3] Stock Performance - Cencora's shares have increased by over 39% in the past 52 weeks, outperforming the S&P 500 Index's rise of 15.1% and the Health Care Select Sector SPDR Fund's decline of 4.1% during the same period [4] Recent Results and Challenges - In Q3 2025, Cencora reported an adjusted EPS of $4 and revenue of $80.66 billion, but shares fell by 2.9% due to a 12.9% decline in operating income from the International Healthcare Solutions segment, increased interest expenses of $81.8 million (up $50.5 million), and a 17.3% rise in operating expenses [5] Analyst Ratings - The consensus rating for Cencora's stock is bullish, with a "Strong Buy" rating from 11 out of 15 analysts, while four analysts recommend a "Hold" rating. The average price target is $339.71, indicating a potential upside of 3.3% from current levels [6]

Core Insights - Cencora, Inc. is a significant player in the pharmaceutical distribution industry, with a market capitalization of $58.7 billion, providing a range of healthcare products and services [1][2] Company Overview - Cencora offers end-to-end pharmaceutical commercialization solutions, over-the-counter healthcare products, home healthcare supplies, and related services to healthcare providers [1] - The company is categorized as a large-cap stock due to its market cap exceeding $10 billion, highlighting its size and influence in the medical distribution sector [2] Financial Performance - In Q3, Cencora reported revenue of $80.7 billion, an increase of 8.7% year-over-year, and adjusted EPS rose by 19.8% to $4 [5] - The company has raised its fiscal 2025 adjusted EPS guidance to a range of $15.85 to $16 [5] Stock Performance - Cencora's stock has seen a year-to-date increase of 34.6% and a 27.3% rise over the past 52 weeks, outperforming the Health Care Select Sector SPDR Fund's marginal gains [4] - Despite a recent drop of 2.2% from its 52-week high of $309.35, the stock has gained 2.5% over the past three months, outperforming the XLV's 1% gain [3][4] Strategic Positioning - The company's strengths include its strategic positioning in the healthcare value chain, a diversified portfolio, and scale-driven bargaining power [2] - Cencora leverages technological capabilities in supply chain management and data analytics to achieve high operational efficiency, with fill rates exceeding 99% [2]